Form 4: Shattuck Labs Insider Buys Shares and Warrants

Shattuck Labs reports insider Stephen Stout acquired 12,805 shares of common stock and accompanying warrants in a private placement.

Summary

• Stephen Stout, an officer of Shattuck Labs, Inc., acquired 12,805 shares of common stock and warrants to purchase an additional 12,805 shares.
• The transaction occurred on May 15, 2026, as part of a private placement that closed on August 25, 2025.
• The combined price per share and accompanying warrant was $0.8677.
• Following the transaction, Mr. Stout beneficially owns 93,366 shares of common stock.
• The warrants are exercisable after the original issuance date until 30 days following the public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety data, and the design of planned Phase 2 trials.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development due to the insider's acquisition of stock and warrants, signaling confidence, but tempered by the delay in reporting and the contingent nature of warrant exercise.

Positives

• Insider purchase indicates confidence in the company's future prospects.
• Acquisition of both stock and warrants suggests a long-term investment perspective.
• The transaction was part of a private placement, potentially indicating strategic investor involvement.

Negatives

• The purchase price of $0.8677 per share and warrant combined is relatively low, suggesting the stock may have been trading at a depressed valuation at the time of the private placement.
• The exercise of warrants is contingent on the announcement of clinical trial data, introducing uncertainty.

Risks

• The exercise of warrants is dependent on the successful announcement of Phase 1 clinical trial data for SL-325, which carries inherent clinical trial risks.
• Future stock price performance is tied to the outcomes of clinical trials and subsequent development phases.
• The private placement occurred in August 2025, and the Form 4 filing is dated May 2026, indicating a significant time lag in reporting this transaction.

Future Outlook

The exercise of warrants is contingent upon the public announcement of data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s).

Industry Context

StockSavvy.ai notes that insider purchases, especially those involving both stock and warrants, can signal strong conviction from management regarding the company's pipeline and future prospects, particularly in the biopharmaceutical sector where clinical trial success is paramount.

Related Party Transactions

• Stephen Stout, an officer of Shattuck Labs, Inc., acquired shares and warrants in a private placement alongside other accredited investors.

Stakeholder Impact

• Shareholders may view the insider purchase positively, indicating management's belief in the company's value.
• The contingent nature of warrant exercise introduces a degree of uncertainty for all stakeholders regarding potential future dilution.

Next Steps

• Public announcement of Phase 1 clinical trial data for SL-325 (receptor occupancy and safety data).
• Announcement of the design of planned Phase 2 clinical trial(s) for SL-325.
• Warrants become exercisable 30 days following the public announcement of the aforementioned clinical trial data and Phase 2 trial design.

Key Dates

Recommendation

The filing indicates an insider purchase, which is generally positive, but the transaction occurred in August 2025 and is only being reported in May 2026. The exercise of warrants is contingent on clinical trial results, introducing significant future uncertainty. Therefore, a 'hold' recommendation is appropriate pending further clinical development updates.

Keywords

Shattuck Labs, STTK, Form 4, Insider Trading, Private Placement, Warrants, Clinical Trials, SL-325, Stephen Stout